Our Mission

BioSwan was founded

Patent applied for anti-CD19 CAR-T cell detection reagent

Participated in the first study of the CAR-T cell quality control organized by Center for Drug Evaluation, NMPA

More than 20 Chinese CAR-T related enterprises adopted Bioswan products

Started clinical studies in companion diagnosis of CAR-T cellular therapies in Shanghai Tongji Hospital and the First Affiliated Hospital
of Zhejiang University

PCT application

First companion diagnosis product for CAR-T cellular therapy that submitted for product classification in China

PHave clients from top international institutions, hospitals and pharmaceutical companies (MGH, MAYO,NIH,UPENN

1 new PCT application

First companion diagnosis product for CAR-T cellular therapy that submitted registration in China

Participated in the drafting of China Expert Consensus on Clinical Management of Toxic and Side Effects of CAR-T Cell Therapies for NHL

Launched overall CAR-T clinical detection protocol (Certified Medical Laboratory, LDT)

Applied for US, European, Japanese patents

The CAR-T flow cytometry kit passed the application for special review of National Innovative Medical Devices.